Contrast-enhanced Ultrasound Market size was over USD 1.87 billion in 2024 and is anticipated to cross USD 3.94 billion by 2037, growing at more than 5.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of contrast-enhanced ultrasound is estimated at USD 1.96 billion. The industry growth is driven by an increase in R&D activities, collaboration, product approvals, and launches.
In other words, ultrasound experts called on the healthcare community in October 2021 to work towards wider use of ultrasound contrast agents so as to offer patients better access to less expensive, safer, and more accurate medical imaging. This is also expected to create opportunities for the CEUS, which is expected to contribute to the growth of the market.
Moreover, the real-time imaging capabilities of contrast-enhanced ultrasound add a layer of diagnostic precision, allowing clinicians to observe dynamic processes within the body, such as blood flow and tissue perfusion, in real-time. This real-time feedback not only aids in accurate diagnosis but also enhances procedural guidance, making it an attractive choice for interventions and therapeutic monitoring.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.9% |
|
Base Year Market Size (2024) |
USD 1.87 billion |
|
Forecast Year Market Size (2037) |
USD 3.94 billion |
|
Regional Scope |
|
Type (Microbubble Contrast Agents, Phase-Change Contrast Agents)
In terms of type, the microbubble contrast agents segment is estimated to gain the largest contrast-enhanced ultrasound market share of 60% in the year 2037. The microbubble contrast agent segment growth can be accounted for on the back of increasing cases of liver-related diseases including cirrhosis and hepatocellular carcinoma.
Liver diseases often require precise imaging for accurate diagnosis and monitoring of lesions, and microbubble contrast agents enhance the visibility of vascular structures and lesions during ultrasound imaging. Around a 25% rise has been recorded annually in the incidence of hepatocellular carcinoma globally in the last decade, reported as per a study.
This rapid growth in liver diseases underscores the critical need for advanced imaging techniques, such as contrast-enhanced ultrasound with microbubble contrast agents, for effective diagnosis and management. Continuous advancements in ultrasound technology, including improvements in transducer design and image processing algorithms, are driving the growth of the microbubble contrast agents segment.
End Users (Hospitals, Diagnostic Imaging Centers, Research and Academic Institutions)
Based on end users, the hospital segment is expected to garner the highest CAGR of 50% during the projected timeframe. Hospitals serve as primary centers for diagnosing and managing liver diseases, and the demand for CEUS in this segment is driven by the need for accurate and non-invasive imaging to assess liver lesions.
The hospital segment growth is assessed to rise due to increasing cardiovascular disease cases recorded globally. Hospitals play a central role in cardiovascular care, and the utilization of CEUS for cardiac imaging contributes to the comprehensive assessment of patients with conditions such as myocardial infarction, heart failure, and valvular disorders.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
|
Technology |
|
North American Market Statistics
The North America region contrast-enhanced ultrasound market is set to observe the highest growth of 33% during the review period. The market in this region is expected to escalate on account of growing technological development in medical imaging, as CEUS, with its application in cardiovascular imaging, plays a crucial role in assessing myocardial perfusion and detecting cardiac abnormalities.
The region's commitment to innovation in healthcare technology drives the integration of advanced imaging modalities into clinical practice. Also, kidney-related disorders like chronic kidney disease and renal vascular abnormalities are becoming common cases in this region.
APAC Market Analysis
The contrast-enhanced ultrasound market in the Asia Pacific region is poised to witness a notable revenue share of 27% by the end of 2037. The need for accurate diagnostic instruments like CEUS is growing as it's a major contributor to morbidity and death in the area.
According to a survey, the frequency of chronic hepatitis B and C infections has increased by 30% across the Asia Pacific area over the last ten years, underscoring the growing prevalence of liver illnesses. The population of the Asia Pacific area is aging quickly, causing a shift in demographics, as a result heart disease is becoming more common as a result of this demographic shift.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?